tbuckley/cabot-search huggingface dataset:
THU0428 Psoriasis Arthritis Is Associated with Periarticular Bone Loss of The Metacarpals
Authors: A. Pfeil, H.H. Thodberg, L. Krojniak, D.M. Renz, L. Reinhardt, P. Oelzner, G. Wolf, J. Böttcher
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The BoneXpert is a new Digital X-ray Radiogrammetry method measures the cortical bone thickness of the metacarpals. <h3>Objectives</h3> The aim of this study was to quantify cortical bone loss in patients with Psoriasis Arthritis (PsA) and to compare these findings with the PsA modified van der Heijde Sharp Score. <h3>Methods</h3> The study includes 104 PsA patients. The BoneXpert method was used to measure the Metacarpal Index (MCI<sub>BX</sub>) at the metacarpal bones (II to IV). Additionally, the T-Score of the MCI (T-Score<sub>MCI</sub>) was calculated. Radiographic severity was evaluated by the PsA modified van der Heijde Sharp Score (Joint Space Narrowing Score and Erosion Score). <h3>Results</h3> For the total PsA study cohort the T-Score<sub>MCI</sub> was significantly reduced with -1.289 ± 1.313 SD. The MCI presented a negative correlation to the Joint Space Narrowing Score (r = -0.558; p&lt;0.001) and Erosion Score (r = -0.714; p&lt;0.001) of the PsA modified van der Heijde Sharp Score. In this context, a severity dependent and PsA-related periarticular demineralization as measured by the MCI<sub>BX</sub> was quantified. The highest reduction was observed for the MCI<sub>BX</sub> with -28.5% (p&lt;0.01) regarding to the Erosion Score and with -21.1% (p&lt;0.01) for the Joint Space Narrowing Score. <h3>Conclusions</h3> Patients with PsA presented also periarticular demineralisation and severity dependent bone loss as measured by the BX using the MCI<sub>BX</sub>. The BX-parameters seem to function as surrogate marker of radiographic progression in PsA and potentially differentiate between different stages of disease manifestation affecting bone structures. <h3>Disclosure of Interest</h3> None declared
Risk of Second Malignant Neoplasm Is Related to TPMT Activity and Duration of MTX/6MP Maintenance Therapy of ALL.
Authors: Kjeld Schmiegelow, Ibrahim Al-Modhawi, Mikael Berendtz, Erik Forestier, Henrik Hasle, Mats Heyman, Jon Kristinsson, Randi Nygaard, Kim Vettenranta
Journal: Blood (2006)
THU0479 Pilot Study of Bone Mass in Heart Transplant Recipients
Authors: L. Bautista Aguilar, A. Salmoral Chamizo, I. Gomez-Gracia, R. Jimenez Gasco, P. Font, J.M. Arizon, M. Ruiz Ortiz, E. Collantes Estévez
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Our objective was to describe changes in bone mineral density (BMD), incidence of fractures and levels of bone remodeling markers in the first year post-heart transplant (postHTX). <h3>Methods</h3> We included patients aged ≥18 years with heart transplant performed in our institution from 01.01.2013 to 31.07.2015, excluding those on antiresorptive or bone forming treatment and pregnant women. Before heart transplant (preHTX) and in the one year postHTX visit, the following data were registered: body mass index, risk factors for osteoporosis, biochemical parameters of bone metabolism, presence of osteopenia or osteoporosis in the densitometric analysis of lumbar spine and femoral neck, presence of fractures in the X-ray of the spine and echocardiographic left ventricular ejection fraction (LVEF). <h3>Results</h3> All 17 patients (age 48±16 years, 12 male) included in the study were treated with calcineurin inhibitors and steroids (mean dose 15 mg/day). At the preTX visit, body mass index was 24,7±3,8 kg/m<sup>2</sup>, obesity was present in 4 patients, DM in 1, kidney stones in 3, excessive alcohol consumption in 1, and 11 patients were ex-smokers. Low BMD was present in 14/17 patients (82%) in the preTX visit: 12 osteopenia (8 men and 4 women) and 2 osteoporosis (1 man and 1 woman); and 15/17 patients (88%) in the one year postTX visit: 9 osteopenia (6 men and 3 women) and 6 osteoporosis (3 men and 3 women). One patient died before the first year postHTX visit. Twelve patients (80%) had a vitamin D blood level &lt;20 ng/ml at the one year postHTX visit. A man presented a spinal fracture in the follow-up. Mean LVEF was 25±6% (preHTX) and 75±8% (postHTX). <h3>Conclusions</h3> In this pilot study, 82% of heart transplant recipients had a low BMD preHTX and 88% at the one year postHTX visit. Moreover, 80% of patients had a vitamin D deficiency at the one year postHTX visit. Larger studies are required to fully evaluate this morbidity and describe clinical predictors. <h3>References</h3> Dalle Carbonare L, Zanatta M, Braga V, Sella S, Vilei MT, Feltrin G, et al. Densitometric threshold and vertebral fractures in heart transplant patients. Transplantation. 2011;92:106–11. Luaces M, Crespo Leiro MG, Paniagua Martin MJ, De Lara JG, Rivas RM, Pinon Esteban P, et al. Bone fractures after cardiac transplantation. Transplant Proc. 2007;39:2393 Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, et al. Frecuency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001;357:342–7. Ebeling PR. Transplantation osteoporosis. Curr Osteoporos Rep. 2007;5:29–37. <h3>Disclosure of Interest</h3> None declared
Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance
Authors: Luca A Lotta, Pawan Gulati, Felix R Day, Felicity Payne, Halit Ongen, Martijn van de Bunt, Kyle J Gaulton, John D Eicher, Stephen J Sharp, Jian'an Luan, Emanuella De Lucia Rolfe, Isobel D Stewart, Eleanor Wheeler, Sara M Willems, Claire Adams, Hanieh Yaghootkar, Nita G Forouhi, Kay-Tee Khaw, Andrew D Johnson, Robert K Semple, Timothy Frayling, John R B Perry, Emmanouil Dermitzakis, Mark I McCarthy, Inês Barroso, Nicholas J Wareham, David B Savage, Claudia Langenberg, Stephen O'Rahilly, Robert A Scott
Journal: Nature Genetics (2016)
ROS-Mediated Upregulation of Noxa Overcomes Drug-Resistance Due to P53-Dysfunction in Chronic Lymphocytic Leukemia.
Authors: Sanne H. Tonino, Jacoline M van Laar, Marinus H. J. van Oers, Jean Y.J. Wang, Eric Eldering, Arnon P. Kater
Journal: Blood (2009)
Polymorphism of the angiotensin receptor but not of other renin-angiotensin system polymorphisms is associated with restenosis after percutaneous coronary intervention: A modulating role for heme oxygenase-1
Authors: PL Van Haelst, PS Monraats, J Wijpkema, M Bruinenberg, AH Zwinderman, F Zijlstra, RJ de Winter, PA Doevendans, J Waltenberger, JW Jukema, RA Tio
Journal: Circulation (2005)
Epigenetic Modulation of Alemtuzumab Mediated Antileukemia Effects and Resistance in T- Cell Prolymphocytic Leukemia
Authors: Kamal Sharma, Mithun Shah, Zainul Hasanali, Vikas Ghai, Katie Broeg, Sara Shimko, August Stuart, Elliot M Epner, Thomas P. Loughran
Journal: Blood (2011)
Detection of cytogenetic aberrations in circulating tumor cells
Authors: Arjan Tibbe, Joost F. Swennenhuis, Leon W. M. M. Terstappen
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

3624 

Introduction: The presence of tumor cells in the blood of patients with metastatic carcinomas has been associated with poor survival prospects. The frequency of these cells can be extremely low and the detection of cytogenetic abnormalities may confirm that these cells are indeed tumor cells especially when only a few CTCs are present and/or the patient is not known to have metastatic disease. Here we introduce a technology that permits the detection of cytogenetic aberrations after CTCs have been identified by the CellSearch™ System. Methods: CTCs from 7.5 mL of blood were identified as Cytokeratin+, CD45- nucleated cells after immunomagnetic enrichment targeting the EpCAM antigen using the CellSearch System. CTCs are identified by the CellTracks® Analyzer at the upper surface of a cartridge where they are held by a magnetic field. For cytogenetic analysis the fluid in the cartridge was removed and the cells fixed while maintaining their original position. Fluorescently labeled probes for chromosome 1, 7, 8 and 17 were introduced into the cartridge and hybridized to the cells. The fixation and hybridization process removes the fluorescent labels used for CTC identification. After hybridization the cartridges were again placed on the CellTracks Analyzer and analyzed for a second time. The fluorescent images of the CTCs identified in the first scan are then combined with the fluorescent images from each of the four chromosomes labels obtained in the second scan. The number of chromosomes 1, 7, 8 and 17 were enumerated for each CTC that was identified in the first scan. The number of chromosomes detected in leukocytes that surrounded the CTCs were used as internal controls. Results: In 7.5 mL of blood from 8 patients with metastatic carcinoma 1 to 7 CTCs were identified. Greater than or less than two copies of chromosome 1, 7, 8 or 17 were detected in all 8 patients. Heterogeneity in the chromosomal abnormalities were not only detected between CTCs of different patients but also among CTCs of the same patient. Of the 21 CTCs examined, 77% showed chromosomal abnormalities and a majority showed an increase in the number of copies of the chromosomes. In contrast more than 80% of the leukocytes examined showed two copies of the chromosomes and none showed an increase in chromosome copy number. Conclusions: Cytogenetic composition of CTCs can be assessed after they have been identified by the CellSearch system. Whether the presence of aneusomic CTCs is related to poor outcome and/or whether the assignment of patients to the poor prognostic group if only one aneusomic CTC is identified can now be investigated. This technology opens avenues to assess gene amplifications in CTCs associated with current and future cancer therapies.
Apoliprotein A-I Mimetic Peptide and Sickle Vasculopathy: Mouse Model Study of Acute Administration.
Authors: Lewis L. Hsu, Valeriani Bead, Lita A. Freeman, Gregory J. Kato, James G Taylor, Katherine C Wood, Biljana Musicki, Constance Tom Noguchi, Dan Berkowitz, Alan T Remaley, Marcelo Amar
Journal: Blood (2009)
Management of the Sponataneous Bleeding Episodes in Factor VII Deficiency. A Prospective Evaluation of the STER,
Authors: Mariasanta Napolitano, Alberto Dolce, Angelika Batorova, Guenter K.H. Auerswald, Jean-Francois Schved, Sergio Siragusa, Jens Bjerre Knudsen, Jorgen Ingerslev, Carmen Altisent, Kaan Kavakli, Umran Caliskan, Tahir S Shamsi, Marie Bertrand, Sophie Aronis, Giovanni Di Minno, Arlette Ruiz-Sáez, Ampaiwan Chuansumrit, Rosario Perez Garrido, Kanjaksha Ghosh, Narges Mirbehbahani, Mehran Karimi, Guglielmo Mariani
Journal: Blood (2011)
Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.
Authors: Steven M. Horwitz, Madeleine Duvic, Youn Kim, Jasmine M Zain, Mary Jo Lechowicz, Patricia Myskowski, Steven Fruchtman, Owen A O'Connor
Journal: Blood (2009)
Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation
Authors: Hideki Nakasone, Fuji Shigeo, Kimikazu Yakushijin, Makoto Onizuka, Akihito Shinohara, Kazuteru Ohashi, Koichi Miyamura, Naoyuki Uchida, Minoko Takanashi, Tatsuo Ichinohe, Yoshiko Atsuta, Takahiro Fukuda, Masao Ogata
Journal: American Journal of Hematology (2016)

Total body irradiation (TBI) has been thought to promote donor cell engraftment in allogeneic hematopoietic cell transplantation (HCT) from alternative donors. However, recent progress in HCT strategies may affect the clinical significance of TBI on neutrophil engraftment. With the use of a Japanese transplant registry database, we analyzed 3933 adult recipients (>15 y.o.) who underwent HCT between 2006 and 2013 from an 8/8 HLA-matched unrelated bone marrow donor (MUD, n = 1367), an HLA-mismatched unrelated bone marrow donor (MMUD, n = 1102), or unrelated cord blood (CBT, n = 1464). Conditioning regimens were divided into five groups: High-TBI-(>8Gy), Low-TBI- (≤8Gy), and no-TBI-myeloablative conditioning (MAC), and Low-TBI- and no-TBI-reduced-intensity conditioning (RIC). In both MUD and MMUD, neutrophil engraftment rate was >90% in each of the five conditioning groups, and TBI was not associated with prompt neutrophil engraftment in multivariate analyses. Conversely, in CBT, TBI regimens had a higher rate of day-30 neutrophil engraftment than no-TBI-regimens: 78% in High-TBI-MAC, 83% in Low-TBI-MAC, and 76% in Low-TBI-RIC versus 65% in No-TBI-MAC, and 68% in No-TBI-RIC (P < .001). Multivariate analyses in CBT demonstrated that TBI-regimens were significantly associated with a higher rate of neutrophil engraftment. Subsequently focusing on CBT patients alone, TBI-regimens were significantly associated with a higher rate of neutrophil engraftment in patients who received CBT with a 4/6 or less HLA allele-match, or who had anti-HLA antibodies. In summary, TBI-regimens had no impact on neutrophil engraftment in the current practice of unrelated bone marrow transplantation. However, in CBT, TBI is still necessary to enhance engraftment.
Identification of Off-Patent Drugs That Reverse Daunorubicin Efflux Mediated by ABCB1 in T-ALL Cells.
Authors: Stuart S. Winter, Debbie M. Lovato, Hadya M. Khawaja, Bruce S. Edwards, Irena D. Steele, Susan M. Young, Tudor I. Oprea, Larry A. Sklar, Richard S. Larson
Journal: Blood (2006)
Multi-Center Prospective Trial on Conditioning with Treosulfan, Fludarabine and ATG Before Allogeneic HSCT from Unrelated Donors.
Authors: Mauricette Michallet, Quoc-Hung Le, Anne Thiebaut, Sophie Ducastelle, Franck E. Nicolini, Nicole Raus, Reza Tabrizi, Krimo Bouabdallah, Didier Blaise, Mohamad Mohty, Catherine Faucher, Sabine Furst, Jacques-Olivier Bay, Eric Hermet, Noel Milpied
Journal: Blood (2007)
Charcot-Marie-Tooth Disease
Authors: Lea Leonardis, Janez Zidar, Borut Peterlin
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PTH-058 Retrospective Analysis of Crohn’s Disease Risks for Further Surgery
Authors: D Chan, M Mendall, D Kumar
Journal: Gut (2016)

<h3>Introduction</h3> Surgery plays an important role in the treatment of Crohn’s disease. Only a few large surgical series have been published in the literature. We describe our own experience and factors that determine risk of reoperation over a ten-year period. <h3>Methods</h3> All Crohn’s disease surgeries at St George’s Hospital from 1 st January 2004 to 31 st December 2013 were identified. A random sample of just over 200 patients was selected; not including patients less than 16 years of age at time of surgery or those who had surgery for perianal disease. Information was collected for weight, height, gender, smoking status as well as their medical and surgical management. Patients whose records were incomplete were contacted by telephone for further information. <h3>Results</h3> There were a total of 154 patients selected who had completed histories. This accounted to just over 10,000 months of follow-up. Surgeries were for bowel resections, strictureplasties or fistula repairs. 80 were male and 74 were female. Mean age of diagnosis was 23 years and 10 months. Mean time from diagnosis to first ever surgery was 5 years and 5 months. Mean time to further surgery was 31 months. 69% were non-smokers, defined as never having smoked more than 100 cigarettes in their lifetime. At the time of surgery 18% had a low BMI, 60.1% had a normal BMI and 21.9% had a high BMI. 72.72% were receiving treatment with the immunomodulators: azathioprine, 6 mercaptopurine or methotrexate. 7.14% were receiving biologic therapy at the time of surgery. 46.7% had albumin levels &lt;35 at time of surgery and mean CRP was 27.15. Cox regression analysis was used to assess for risk for further surgery and covariates of: age of diagnosis, number of previous surgeries, time from diagnosis to first ever surgery for Crohn’s disease, treatment with immunomodulators, albumin at time of surgery, change in albumin at 1 year follow up, sex, BMI and smoking status. Significant risk for further surgery was found in those that had ever smoked and low BMI (hazard ratio 4.775 and 2.147 respectively). Importantly previous surgery, albumin and age of diagnosis were not a risk factor for recurrent surgery (hazard ratios 1.016, 0.962 and 1.198 respectively). <h3>Conclusion</h3> We review over 10,000 months of follow-up in a selection of Crohn’s disease patients. We have identified significant risks for further surgery of smoking and low BMI (probably a reflection of more severe disease). It continues to be important to address these risk factors as well as continue to try and identify other cofactors and markers that can be useful in predicting course of disease. <h3>Disclosure of Interest</h3> None Declared
Redefining Mutational Profiling Using RNA-Seq: Insight into the Functional Mutational Landscape of Multiple Myeloma
Authors: David Mosen-Ansorena, Niccolo Bolli, Mehmet K Samur, Florence Magrangeas, Stephane Minvielle, Kenneth C Anderson, Peter J Campbell, Hervé Avet-Loiseau, Giovanni Parmigiani, Nikhil C. Munshi
Journal: Blood (2015)
Modification of An Interactive Surface in the C1 Domain Reduces Immune Responses to FVIII in a Mouse Model of Hemophilia A
Authors: Aleksandra Wroblewska, Simon D van Haren, Eszter Herczenik, Aleksandra Rusiecka, Paul H Kaijen, Anja ten Brinke, Koen Mertens, Jan Voorberg
Journal: Blood (2011)
SAT0427 The Absence of Symptom in Subjects with Advanced Knee OA
Authors: K.M. Son, H.S. Lee, D.H. Kim, M.C. Paik, D.G. Jang, S.Y. Lee, H.A. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although osteoarthritis (OA) is predominantly considered as a disease of cartilage, articular cartilage is an aneural tissue, and there is a consensus that the association between knee radiographic OA and knee pain is modest. <h3>Objectives</h3> To investigate the prevalence of asymptomatic subjects with advanced knee OA, we examined databases obtained from 2 Korean community residents. <h3>Methods</h3> Subjects included were from Hallym Aging Study (HAS) or from the Korean National Health and Nutrition Examination Survey (KNHANES, year 2010–2012). Participants in each study were asked knee-specific questions regarding the presence of knee pain. Radiographic evaluations consisted of weight-bearing anteroposterior, weight-bearing semi-flexed knee radiographs. For HAS cohort, MRI of the knee was available. Each knee was evaluated for the presence of osteophytes, joint space narrowing, subchondral sclerosis, and cysts, and was graded for overall evidence of radiographic OA using the K-L grade. Advanced knee OA was defined as K-L grade 4 (large osteophytes, severe joint space narrowing, and/or bony sclerosis). Clinical factors associated with the presence of knee pain were evaluated with multivariate logistic regression analysis. <h3>Results</h3> Included were 504 subjects from HAS and 8679 from KNHANES. Advanced knee OA was identified in 47 (9.3%) and 685 (7.8%) in HAS and KNHANES, respectively. The mean age of the study subjects were 72.5 years and 16.5% were male. Two hundred twenty five subjects (44.3%) did not report any pain despite having K-L grade 4 OA. Female, non-smoker, the presence of osteoporosis, and lower education were significantly associated with knee pain. After multivariate association, female and osteoporosis was significantly associated with the presence of knee pain. Advanced OA subjects without knee pain did not differ from non-OA subjects in the general physical health measured with the short-form (SF-12), except for the physical functioning. Regardless of the presence of pain, MRI finding such as summary cartilage score, bone marrow lesion score, the presence of synovitis and effusion was similar in advanced OA subjects. <h3>Conclusions</h3> Our community study showed that a significant number of subjects with K-L grade 4 OA was asymptomatic. The guidance of therapeutic decision merely based on imaging study as well as treatment option focusing solely on cartilage engineering should be viewed with caution. <h3>Disclosure of Interest</h3> None declared
PTU-141 A Pragmatic Randomised Controlled Trial of Healing Therapy in a Gastroenterology Outpatient Setting
Authors: R lee, T Kingstone, L Roberts, S Edwards, A Soundy, P Shah, MS Haque, S Singh
Journal: Gut (2016)

<h3>Introduction</h3> To determine benefits of healing therapy as an adjunct to conventional management in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). <h3>Methods</h3> : 200 outpatients with IBS or IBD were randomised to either conventional treatment or conventional plus 5 sessions of healing therapy. After 12 weeks Controls also had healing therapy. Outcomes used were, the Measure Yourself Medical Outcomes Profile (MYMOP). IBS-QOL and IBDQ and symptom measures. <h3>Results</h3> There was a significant improvement in the MYMOP score at week 6 (p &lt; 0.001) which was maintained to week 12 (p &lt; 0.001) and 24 (p &lt; 0.001). Improvements in MYMOP were significantly greater in the intervention group at both 6 (p &lt; 0.001) and 12 weeks (p &lt; 0.001) with effect sizes of 0.7 (95% CI: 0.4 to 1.1) and 0.8 (95% CI: 0.4 to 1.2). Condition specific data for IBS showed that most QoL dimensions had a significant minimum 10 point score improvement at 6 and 12 weeks. The overall score improvement was 12.9 units at week 6 (p &lt; 0.001), 12.4 units at week 12 (p &lt; 0.001) and 13.8 units at 24 weeks (p &lt; 0.001). In IBD there was also similar score improvement but only up to week 12 associated with improved social (p &lt; 0.001) and bowel (p &lt; 0.001) functions. Between group difference identified for QoL scores in IBS at both week 6 (p &lt; 0.001) and 12 (p &lt; 0.001) but only for week 12 (p &lt; 0.001) in the IBD group. <h3>Conclusion</h3> The addition of healing therapy in IBS was associated with improvements in symptoms and QoL in IBS, and to a lesser extent in IBD. <h3>Disclosure of Interest</h3> None Declared
Acute GVHD in AML and MDS Patients Receiving Matched Related Donor (MRD) Reduced-Intensity Conditioning Allogeneic Hematopoietic Progenitor Cell Transplant (RIC-AHPCT) Correlates with Major Histocompatibility Complex Class I-Related Molecule A (MICA) Gene Polymorphisms,
Authors: Ronald Sobecks, Aiwen Zhang, Lisa Rybicki, Dawn Thomas, Paul Kawczak, Matt Kalaycio, Steven Andresen, Brad Pohlman, Robert Dean, Edward A. Copelan, Rabi Hanna, Hien Duong, Jaroslaw P. Maciejewski, Brian J. Bolwell, Medhat Askar
Journal: Blood (2011)